Pierre Massion
Faculty Member
Last active: 1/11/2018

Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma.

Shinohara ET, Gonzalez A, Massion PP, Chen H, Li M, Freyer AS, Olson SJ, Andersen JJ, Shyr Y, Carbone DP, Johnson DH, Hallahan DE, Lu B
Cancer. 2005 103 (8): 1685-92

PMID: 15742356 · DOI:10.1002/cncr.20951

BACKGROUND - Survivin, which is a member of the inhibitor of apoptosis protein gene family, regulates both programmed cell death and mitosis. It has been shown that survivin expression and its subcellular localization both have prognostic value for patients with malignant disease. In this study, the authors investigated whether nuclear or cytoplasmic staining of survivin was a prognostic marker for patients with lung carcinoma.

METHODS - Paraffin-embedded tissue blocks from 144 patients with Stage I and II resected nonsmall cell lung carcinoma (NSCLC) were obtained for immunohistochemical staining. Three specimens from each patient were prepared and stained with a survivin-specific antibody. Nuclear and cytoplasmic staining was graded from 1 to 3 based on intensity.

RESULTS - Patients who had nuclear staining for survivin had a significantly increased risk of disease recurrence (hazard ratio, 2.95; P = 0.0046) and death (hazard ratio, 2.74; P = 0.0086).

CONCLUSIONS - The nuclear presence of survivin may be an independent biomarker for disease recurrence and overall survival in patients with resected Stage I and II NSCLC.

(c) 2005 American Cancer Society.

MeSH Terms (21)

Adult Aged Aged, 80 and over Biomarkers, Tumor Carcinoma, Non-Small-Cell Lung Cell Nucleus Cytoplasm Female Humans Immunoenzyme Techniques Inhibitor of Apoptosis Proteins Lung Neoplasms Male Microtubule-Associated Proteins Middle Aged Neoplasm Proteins Neoplasm Recurrence, Local Neoplasm Staging Prognosis Survival Rate Survivin

Connections (1)

This publication is referenced by other Labnodes entities: